# Delphinus Medical Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/delphinus-medical-technologies

- Industry: Healthcare
- Headquarters: Novi, US
- Website: www.delphinusmt.com
- Total disclosed funding: $89M
- Latest round: Series D (Aug 30, 2022)
- Investors on record: 7

## About

Delphinus Medical Technologies, Inc. develops advanced breast cancer screening solutions, most notably the SoftVue™ 3D Whole Breast Ultrasound Tomography system, which enhances detection capabilities for women with dense breast tissue.Founded in 2010 and headquartered in Novi, US, Delphinus Medical Technologies, Inc. specializes in breast cancer screening technology. The company has engaged in 8 deals by June 2023, with its latest funding round being a Series E raising USD 5.00 mn from Trinity Capital Investment. The current CEO is Scott White.Delphinus Medical Technologies specializes in innovative breast cancer screening solutions, with its flagship product being the SoftVue™ 3D Whole Breast Ultrasound Tomography system. This FDA PMA-approved technology is specifically designed for the screening of women with dense breast tissue, addressing the significant limitations of traditional mammography, which can miss over 50% of cancers in this demographic. The SoftVue system utilizes a unique circular triple-acoustic transducer setup, incorporating over 2,000 transducer elements to deliver comprehensive imaging capabilities. By combining reflected echoes with sound speed and attenuation signals, SoftVue enables healthcare professionals to distinguish between normal and abnormal breast tissue more effectively. The company primarily serves healthcare providers such as hospitals and imaging centers across the United States, with recent installations noted in facilities including McLeod Regional Medical Center and UR Medicine.Delphinus Medical Technologies generates revenue through direct sales and potential partnerships with healthcare institutions, primarily focusing on B2B transactions. The business model revolves around the sale and installation of the SoftVue system, which is complemented by ongoing service agreements and training for medical staff. Customers, including hospitals and imaging centers, benefit from enhanced screening capabilities that improve cancer detection rates, particularly in women with dense breast tissue. Revenue is derived from the initial purchase of the SoftVue system, as well as follow-up services such as maintenance and software updates. While specific pricing plans for the SoftVue system and associated services are proprietary, the company’s transactional structure is built on adding value to healthcare providers through advanced imaging technology and comprehensive support.In June 2023, Delphinus Medical Technologies, Inc. raised USD 5 mn in Series E funding from new investor Trinity Capital Investment. The company will use the funding to continue to scale operations and broaden its impact in the global healthcare community.

## Funding rounds

- Series D, Aug 30, 2022, $30M — Beringea, Venture Investors, Arboretum Ventures, North Coast Technology Investors, Hopen Life Science Ventures, Waycross Ventures
- Series C, Sep 10, 2015, $40M — Beringea, Venture Investors, Arboretum Ventures, North Coast Technology Investors, Hopen Life Science Ventures, Waycross Ventures
- Series B, Sep 3, 2013, $11M — Beringea, Arboretum Ventures, North Coast Technology Investors
- Series A, May 25, 2010, $8M — Beringea, Arboretum Ventures, North Coast Technology Investors, Wolverine Venture Fund

## Investors

- Beringea (https://capitalatlas.ai/funds/beringea) — Series A, Series B, Series C, Series D
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series A, Series B, Series C, Series D
- North Coast Technology Investors (https://capitalatlas.ai/funds/north-coast-technology-investors) — Series A, Series B, Series C, Series D
- Wolverine Venture Fund (https://capitalatlas.ai/funds/wolverine-venture-fund) — Series A
- Venture Investors — Series C, Series D
- Hopen Life Science Ventures (https://capitalatlas.ai/funds/hopen-life-science-ventures) — Series C, Series D
- Waycross Ventures — Series C, Series D